Sophie brings over a decade of experience in the early development of T-cell based therapeutics, gained across several oncology-focused biotech companies.

Following her involvement in the improvement of soluble TCRs and CAR-Ts, she believes that off-the shelf cancer vaccines represent the next frontier in the oncologic armamentarium.

With a strong foundation in immunology, she has transitioned into a strategic role focused on fast-tracking the development of cancer vaccines.  

Driven by a commitment to seamlessly translate Epitopea’s research into clinical application, Sophie leads cross-functional efforts across clinical, regulatory, pre-clinical, and CMC. Sophie holds a PhD from University College London.